Showing all 2 results
Adefovir Dipivoxil Tablets
FreeProduct Composition & Strengths
We supply this therapeutic in the globally accepted standard therapeutic strength optimized for adult daily maintenance therapy.
Active Ingredient Standard Strength Primary Clinical Target Adefovir Dipivoxil IP / BP / USP 10 mg The Polymerase Blocker: Daily oral dose to suppress chronic Hepatitis B viral loads. Excipients Pharma Grade The Matrix: High-stability lactose/microcrystalline cellulose binders. Lamivudine Tablets
FreeProduct Composition & Available Portfolio strengths
We manufacture Lamivudine across the precise compendial strengths mandated to manage either targeted chronic hepatic monotherapy or high-potency systemic combination antiretroviral protocols.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Lamivudine USP / BP / IP 100 mg Oral Solid Film-Coated Tablet Chronic Hepatitis B (HBV): Low-dose configuration optimized for standalone daily suppression of active hepatic viral replication. Lamivudine USP / BP / IP 150 mg Oral Solid Film-Coated Tablet Standard Antiretroviral (HIV): Baseline strength designed for twice-daily co-administration or integration into standard multi-drug ARV regimens. Lamivudine USP / BP / IP 300 mg Oral High-Potency Solid Tablet High-Compliance Antiretroviral (HIV): Standard adult once-daily high-dose format engineered to optimize long-term patient compliance.
